{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Adaptive Biotechnologies Corp.
Adaptive Biotechnologies Corp. Hits New 52-Week High of $17.14
Adaptive Biotechnologies Corp. achieved a new 52-week high of USD 17.14 on October 15, 2025, marking significant growth from its previous low. The company, with a market cap of USD 1,910 million, has shown a remarkable one-year performance, despite remaining in a loss-making position.
Adaptive Biotechnologies Corp. Hits New 52-Week High of $15.94
Adaptive Biotechnologies Corp. achieved a new 52-week high of USD 15.94 on October 13, 2025, reflecting significant growth from its previous low. Operating in the Pharmaceuticals & Biotechnology sector, the company has shown impressive performance over the past year, despite being loss-making and lacking a dividend yield.
Adaptive Biotechnologies Hits Day High with 8.36% Surge in Stock Price
Adaptive Biotechnologies Corp. has shown notable stock performance, with significant gains over the past month and year, outpacing the S&P 500. The company reported its highest quarterly net sales and reduced raw material costs, although it faces challenges with negative EBITDA and a high debt-to-equity ratio.
Adaptive Biotechnologies Corp. Hits New 52-Week High of $15.57
Adaptive Biotechnologies Corp. achieved a new 52-week high of USD 15.57 on October 8, 2025, reflecting significant growth from its previous low. The company, with a market cap of USD 1,910 million, has shown a remarkable one-year performance, despite being in a loss-making position and having a unique financial structure.
Adaptive Biotechnologies Corp. Hits New 52-Week High of $15.26
Adaptive Biotechnologies Corp. achieved a new 52-week high of USD 15.26 on October 1, 2025, reflecting a substantial increase over the past year. Despite its strong stock performance, the company operates at a loss, with a high price-to-book ratio indicating a premium valuation in the biotechnology sector.
Adaptive Biotechnologies Corp. Hits New 52-Week High at $15.04
Adaptive Biotechnologies Corp. has achieved a new 52-week high, reflecting a significant performance increase over the past year. The company, with a market capitalization of USD 1,910 million, shows strong momentum in the Pharmaceuticals & Biotechnology sector despite being loss-making and lacking a dividend yield.
Adaptive Biotechnologies Hits Day High with 13.94% Surge in Stock Price
Adaptive Biotechnologies Corp. has seen a notable rise in stock performance, achieving a significant annual growth rate. The company reported record net sales and reduced raw material costs, although it faces challenges with negative EBITDA and a specific debt-to-equity ratio. High institutional holdings indicate strong investor support.
Adaptive Biotechnologies Stock Hits Day Low of $12.72 Amid Price Pressure
Adaptive Biotechnologies Corp. saw a significant stock decline today, reaching an intraday low. Despite this, the company has demonstrated strong performance metrics over the past year, including substantial net sales and reduced raw material costs. However, it faces challenges such as negative EBITDA and a high debt-to-equity ratio.
Adaptive Biotechnologies Corp. Hits New 52-Week High of $14.47
Adaptive Biotechnologies Corp. achieved a new 52-week high, reflecting a substantial increase in stock performance over the past year. As a small-cap company in the Pharmaceuticals & Biotechnology sector, it has shown resilience despite financial challenges, with a focus on growth rather than returning capital to shareholders.
Adaptive Biotechnologies Corp. Hits New 52-Week High at $14.27
Adaptive Biotechnologies Corp. achieved a new 52-week high of USD 14.27 on September 22, 2025, reflecting a significant growth trajectory over the past year. The company, with a market capitalization of USD 1,910 million, operates in the Pharmaceuticals & Biotechnology sector and has shown impressive performance compared to the S&P 500.
Adaptive Biotechnologies Corp. Hits New 52-Week High of $13.90
Adaptive Biotechnologies Corp. achieved a new 52-week high of USD 13.90 on September 19, 2025, reflecting a significant increase over the past year. With a market capitalization of USD 1,910 million, the company continues to navigate the competitive pharmaceuticals and biotechnology sector despite being loss-making.
Is Adaptive Biotechnologies Corp. technically bullish or bearish?
As of September 10, 2025, Adaptive Biotechnologies Corp. shows a bullish technical trend with strong momentum indicators, outperforming the S&P 500 significantly year-to-date and over the past year.
Is Adaptive Biotechnologies Corp. overvalued or undervalued?
As of November 12, 2019, Adaptive Biotechnologies Corp. is considered overvalued and rated as risky due to negative financial metrics, including a Price to Book Value of 8.05 and significant losses reflected in its ROCE and ROE, despite a strong recent stock performance.
Adaptive Biotechnologies Corp. Hits Day High with 7.41% Surge
Adaptive Biotechnologies Corp. has shown notable stock activity, achieving an intraday high and significant annual returns. The company has reported positive operational metrics, including improved cash flow and reduced raw material costs. Despite being classified as risky due to negative EBITDA, it enjoys full institutional ownership, enhancing its market position.
Adaptive Biotechnologies Corp. Hits New 52-Week High of $13.79
Adaptive Biotechnologies Corp. achieved a new 52-week high of USD 13.79 on September 18, 2025, reflecting significant growth from its previous low. The company, with a market cap of USD 1,910 million, has shown a remarkable one-year performance, despite being in a loss-making position and lacking dividend yield.
Is Adaptive Biotechnologies Corp. overvalued or undervalued?
As of November 12, 2019, Adaptive Biotechnologies Corp. is considered risky and overvalued due to negative earnings, poor return metrics, and high valuation ratios compared to peers, despite a strong recent stock performance.
Is Adaptive Biotechnologies Corp. technically bullish or bearish?
As of June 2, 2025, the technical trend is bullish with strong indicators like the weekly MACD and Bollinger Bands supporting this view, although caution is advised due to a bearish monthly RSI.
Who are in the management team of Adaptive Biotechnologies Corp.?
As of March 2022, the management team of Adaptive Biotechnologies Corp. includes Chad Robins as Executive Chairman and CEO, with Peter Neupert as Lead Independent Director and independent directors Kevin Conroy, Eric Dobmeier, David Goel, and Michelle Griffin.
What does Adaptive Biotechnologies Corp. do?
Adaptive Biotechnologies Corp. is a biotechnology company that develops diagnostics and treatments leveraging the adaptive immune system. As of March 2025, it reported net sales of $52 million and a net loss of $30 million, with a market cap of approximately $1.54 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
